EXCLUSIVE: Sen. Eric Schmitt says TrumpRx is driving down prescription costs, calls portal “important” for patients

Sen. Eric Schmitt is pointing to President Donald Trump’s TrumpRx program as a clear affordability win, saying patients are already seeing lower prescription drug costs through the initiative.

“You’ve had prescription costs go way down,” Schmitt told the Washington Reporter in a recent interview. “Having direct access to that portal so that people can buy the drugs that they need, and having it be cheaper is important.”

TrumpRx, launched earlier this year, directs patients to lower-cost options for branded prescription drugs through manufacturer-backed pricing and direct purchasing channels. President Trump has cited the program as a substantial win, resulting in substantially lower prices through negotiations, after years of Democrats failing to lower prices through costly price controls. 

President Trump has pointed to price reductions of up to 90 percent on medications, a statistic that has helped drive massive Republican support on Capitol Hill.

Sen. Schmitt’s strong support for TrumpRX is noteworthy, as Schmitt is widely considered a rising star in the Senate Republican caucus, having successfully pushed through DOGE cuts in 2025 and been a leading voice pushing for President Trump’s agenda. The left, too, has noticed Sen. Schmitt, with Mother Jones featuring him in an article titled, “The Most Dangerous Man in the US Senate?”

The Washington Reporter has previously reported on GOP leaders embracing the program as a tangible affordability win, including comments from Sen. John Barrasso (R., Wyom.) and Sen. Roger Marshall (R., Kan.) , who described TrumpRx as a major step toward lowering health care costs. 

Schmitt’s comments add to a growing drumbeat from Republicans pointing out that TrumpRx as one of the party’s strongest economic arguments heading into the election cycle. Lawmakers have emphasized the program’s direct-to-consumer structure and its focus on lowering out-of-pocket costs without expanding federal bureaucracy.

Outside of Capitol Hill, TrumpRx has also drawn attention from unexpected corners. Entrepreneur Mark Cuban told the Washington Reporter in a recent interview that the program is saving patients money and should be expanded, underscoring the broader appeal of efforts to increase price transparency and competition in the prescription drug market.

For Schmitt, the argument is straightforward: lower prices and easier access matter to constituents.

“People can buy the drugs that they need,” he said, “and having it be cheaper is important.”